• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

Chagas disease: Shorter treatment just as effective as longer one, according to study in Bolivia published by The Lancet

The ‘game-changing’ findings pave the way for the adoption of a new regimen with fewer side effects and improved adherence for people living with Chagas disease

Home > Press releases

Chagas disease: Shorter treatment just as effective as longer one, according to study in Bolivia published by The Lancet

The ‘game-changing’ findings pave the way for the adoption of a new regimen with fewer side effects and improved adherence for people living with Chagas disease

Nurse holding a test tube
Cochabamba / Rio de Janeiro / Barcelona — 6 Apr 2021
  • English
    • English
    • Español
    • Português
    • 日本語

A two-week treatment with the antiparasitic drug benznidazole for adults with chronic Chagas disease has similar efficacy and significantly fewer adverse effects than the current standard eight-week treatment, according to a study published by The Lancet Infectious Diseases.

These results are extracted from a Phase II clinical trial that was carried out in three centres in Bolivia, led by the Drugs for Neglected Diseases initiative (DNDi) and funded by the Global Health Innovative Technology Fund (GHIT).

‘A shorter treatment that is just as effective and much safer than the current one could be a game-changer for people with Chagas disease, who live for years with this debilitating disease,’ said Dr Faustino Torrico, co-principal investigator of the trial and President of the CEADES Foundation.

The trial was carried out between 2016 and 2018, in cooperation with many partners around the globe, including the Bolivian non-profit CEADES (Science and Applied Studies Foundation for Health and Environment Development), the Barcelona Institute for Global Health (ISGlobal), a centre supported by the ”La Caixa” Foundation, the Japanese pharmaceutical company Eisai Co., Ltd., and the Argentinian pharmaceutical company Elea.

Chagas disease affects an estimated six million people globally and can cause irreversible, life-threatening damage to the heart and other vital organs if not treated. Current treatment with benznidazole, one of the two drugs used to treat the disease, is effective but has limitations: the treatment course lasts 60 days and around 20% of patients stop it due to serious side effects, which include gastric intolerance, skin rashes, and neuromuscular problems.  

‘This was the first placebo-controlled study to compare different durations and doses of treatment with benznidazole, alone or in combination with fosravuconazole (E1224),’ said Joaquim Gascon, co-principal investigator and Director of the Chagas Initiative at ISGlobal.

Benznidazole was provided by Elea and fosravuconazole (E1224) was provided by Eisai Co., Ltd.

‘Although we could not verify the efficacy of the combination treatment of benznidazole and fosravuconazole (E1224) compared to treatment with benznidazole alone, the study confirmed the new regimen, with fewer adverse effects, which has potential to be a new standard treatment. We are pleased to have contributed to the creation of this evidence. Based on our human health care (hhc) corporate philosophy, we will continue to work with public and private partners including DNDi for the elimination of NTDs,’ said Dr Kappei Tsukahara, Vice President, Chief Data Officer and Head of Tsukuba Research Laboratories at Eisai Co., Ltd.

The objective of the BENDITA (Benznidazole New Doses Improved Treatment & Therapeutic Associations) clinical trial was to find regimens that are as effective as the standard treatment while producing fewer side effects to improve patient adherence to treatment. ‘This study provides hope for people affected by this neglected disease, as a shorter treatment will remove some concerns of caregivers and patients and will improve treatment adoption,’ said Sergio Sosa Estani, Head of the Chagas Clinical Programme at DNDi and researcher at CONICET (National Scientific and Technical Research Council) in Argentina.

Confirmatory studies with a larger number of patients in Argentina and other countries will validate these findings before the new regimen can be adopted by Chagas patients. DNDi will soon launch a Phase III clinical trial in Argentina in partnership with ELEA-Phoenix and Mundo Sano Foundation to confirm the efficacy and the safety of this two-week regimen of benznidazole.

This upcoming study should also contribute to simplifying the treatment of young girls and woman of child-bearing age to prevent congenital transmission from previously treated mothers to their babies. As mothers can transmit Chagas disease to their children, the trial could help lead to the elimination of Chagas disease as a public health problem, which is one of the World Health Organization’s Neglected Tropical Disease (NTD) Roadmap objectives for the next decade.

‘This is truly a remarkable achievement made possible by international collaboration. With this new finding, we opened up a new way to provide a new shorter regimen for patients. We appreciate patients, their families, healthcare professionals, and all the partners who joined the BENDITA study. We also thank Eisai for providing their drug fosravuconazole (E1224) for the combination treatment arms in the clinical trial to compare efficacy and safety,’ said Ms. Catherine Ohura, the CEO and Executive Director of GHIT.

For this study, DNDi received financial support from the Global Health Innovative Technology Fund, Japan; the UK Department for International Development (UK Aid); the German Federal Ministry of Education and Research through KfW; the Dutch Ministry of Foreign Affairs; the Brazilian Ministry of Health; the Associação Bem-Te-Vi Diversidade, Brazil; the Fundação Oswaldo Cruz (Fiocruz), Brazil; and the Starr International Foundation, Switzerland.

For its overall mission, DNDi also receives funding from the Swiss Agency for Development and Cooperation, Switzerland and Médecins Sans Frontières International. Non-conventional serology assays were performed at the Biomolecule Analysis Core Facility (currently, Biomolecule Analysis and Omics Unit) at the Border Biomedical Research Center, University of Texas at El Paso, funded by the National Institute on Minority Health and Health Disparities.

About DNDi

A not-for-profit research and development organization, DNDi works to deliver new treatments for neglected patients, those living with Chagas disease, sleeping sickness (human African trypanosomiasis), leishmaniasis, filarial infections, mycetoma, paediatric HIV, and hepatitis C. DNDi is also coordinating a clinical trial to find treatments for mild-to-moderate COVID-19 cases in Africa. Since its inception in 2003, DNDi has delivered eight new treatments to date, including new drug combinations for kala-azar, two fixed-dose antimalarials, and DNDi’s first successfully developed new chemical entity, fexinidazole, approved in 2018 for the treatment of both stages of sleeping sickness. dndi.org

Media contact

DNDi Latin America
Marcela Dobarro
mdobarro@dndi.org
+55 21 981149429

DNDi Geneva
Frédéric Ojardias
fojardias@dndi.org  
+41 79 431 62 16

Photo credit: Ana Ferreira-DNDi

Clinical trials Chagas disease Latin America

Read, watch, share

Loading...
Statements
27 May 2025

DNDi interventions at the 78th World Health Assembly

Press releases
22 May 2025

Six African nations commit to eliminate deadly neglected disease visceral leishmaniasis

Videos
20 May 2025

The Children of the Sierra

Press releases
13 May 2025

First all-oral treatment for a rare but deadly strain of sleeping sickness now available and being used to treat patients in endemic countries in Africa

Statements
8 May 2025

DNDi’s briefing note for 78th World Health Assembly

Marco Krieger
News
30 Apr 2025

Message on the passing of Dr Marco Aurélio Krieger, Vice-President of Production and Innovation in Health, Fiocruz

Screening activities in village in Guinea
News
25 Apr 2025

Statements from Dr Luis Pizarro and Daisuke Imoto about the Hideyo Noguchi Africa Prize awarded to DNDi

Two man outside of a hospital talking with a nurse
Press releases
24 Apr 2025

Liverpool clinical trial aims to advance life-changing treatment for a deadly parasitic disease

VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License